目的探讨急性冠状动脉综合征(ACS)患者住院期间短期大剂量阿托伐他汀强化治疗的有效性及安全性。方法选取ACS患者355例,其中强化组180例(入院即给予阿托伐他汀80mg,无论是否行冠脉介入治疗,均在住院期间予阿托伐他汀80mg/晚),常规组175例(入院起予阿托伐他汀20mg/晚)。两组患者均于入院时及入院后1周后均予生化检查[包括有效性指标(TG、TC、HDL-C、LDL-C)及安全性指标(ALT、AST、Cr、CK、CK-MB)]并记录结果。结果两组患者治疗1周后,TC、TG、LDL-C水平均显著下降,HDL-C水平均显著升高,差异均有统计学意义(均P<0.01);与常规组比较,强化组TG水平升高更明显,差异有统计学意义(P<0.05)。两组患者治疗1周后Cr、CK、CK-MB均较治疗前明显改善,差异均有统计学意义(均P<0.01);与常规组比较,强化组ALT及AST水平升高更明显,差异均有统计学意义(均P<0.01)。结论 80mg短期阿托伐他汀强化治疗的安全性与20rng相同,能迅速有效降低患者TG、TC和LDL-C水平,提高HDL-C水平,临床获益更大。 Objective To investigate the efficacy and safety of short-term high-dose atorvastatin in patients with acute coronary syndrome (ACS) during hospitalization. Methods A total of 355 patients with ACS were enrolled in this study. Among them, 180 patients in the intensive group (atorvastatin 80 mg on admission, atorvastatin 80 mg / night during hospitalization, regardless of coronary intervention) Starting atorvastatin 20mg / night). Both groups were biochemically tested at admission and one week after admission [including validity indicators (TG, TC, HDL-C, LDL-C) and safety indicators (ALT, AST, Cr, CK and CK-MB) ] And record the result. Results The levels of TC, TG and LDL-C in both groups decreased significantly and the level of HDL-C significantly increased after one week of treatment (all P <0.01). Compared with the conventional group, TG levels increased more significantly, the difference was statistically significant (P <0.05). The levels of Cr, CK and CK-MB in the two groups were significantly improved after treatment for 1 week (all P <0.01). Compared with the conventional group, the levels of ALT and AST in the intensive group were significantly increased, The difference was statistically significant (both P <0.01). Conclusions The safety of 80mg short-term atorvastatin is the same as that of 20rng. It can effectively reduce the level of TG, TC and LDL-C and increase the level of HDL-C in patients with clinical benefit.